BRIDGEWATER, N.J., Oct. 7, 2019 /CNW/ -- Bausch + Lomb, a leading
global eye health company and wholly owned subsidiary of Bausch
Health Companies Inc. (NYSE/TXS: BHC), today announced that 14 new
scientific poster and clinical presentations involving the
company's products, as well as data from the company's Antibiotic
Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance
study, will be presented during the Annual Meetings of the American
Academy of Ophthalmology and American Academy of Optometry in
San Francisco (Oct. 12-15, 2019) and Orlando (Oct. 26-30,
2019), respectively.
"Bausch + Lomb is committed to supporting research designed to
generate learnings about our products as well as broader insights
for the eye health community – such as the unique ARMOR
surveillance study," said Joe
Gordon, U.S. president, Bausch + Lomb. "We invite eye care
professionals attending both meetings to learn more about the
results of these data to help inform them how they can better
address the needs of their patients."
The full schedule of all scientific poster and clinical
presentations that will include Bausch + Lomb products and the
ARMOR study results is as follows:
American Academy of Ophthalmology
- Asbell, P et al. "Ten-Year Antibiotic Resistance Trends From
Ocular Pathogens Collected in the ARMOR Surveillance Study."
Saturday, Oct. 12, 2019 at
9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
- DeCory H et al. "Antibiotic Resistance Among Intraocular
Bacterial Pathogens Collected Over 10 Years in ARMOR." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct.
15, 2019 at 1:00 p.m.
- Harasymowycz, P et al. "Effectiveness of Latanoprostene Bunod
in Treating OAG and OHT: Network Meta-analysis." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct.
15, 2019 at 1:00 p.m., also
available as part of e-poster discussion session on Sunday, Oct. 12, 2019 from 12:15-12:45 e-poster
Lounge, Station 3
- Liang, E et al. "Retinal Image Simulations of Aspheric IOLs
With Nominal Tilt and Decentration." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct.
15, 2019 at 1:00 p.m.
- Packer, M et al. "Optimizing Refractive Outcomes With a New
Vergence-Based Algorithm for a Neutral Aspheric Monofocal Toric
IOL." Saturday, Oct. 12, 2019 at
9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m., also available as part of e-poster
discussion session on Monday, Oct. 14,
2019 from 1:15-2:15 p.m.,
e-poster Lounge, Station 5
- Pizio, H et al. "Energy-Fluid Metrics Analysis of Patients
Undergoing Vacuum-Based Phacoemulsification From Cloud-Based
Database." Saturday, Oct. 12, 2019 at
9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
- Rocha, K. et al. "Analysis of Static and Dynamic Factors
Associated With Pseudoaccommodation in Monofocal IOLs."
Friday, Oct. 11, 2019 at 7:00 a.m. to Tuesday, Oct.
15, 2019 at 1:00 p.m.
- Stephenson, Dee G et al. "Retinal Image Simulations of Aspheric
Toric IOLs Under Conditions of Tilt and Decentration." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct.
15, 2019 at 1:00 p.m.
American Academy of Optometry
- Cavet M et al. "Loteprednol Etabonate (Submicron) 0.38% Gel for
the Reduction of Inflammation and Pain following Cataract Surgery:
Integrated Analysis of Three Phase 3 Studies." Poster #42, Exhibit
Hall WD1, Orange County Convention
Center, Thursday, Oct. 24, 2019 from
4:30 to 6:30 p.m. ET.
- DeCory H et al. "Real-world Persistence with Latanoprostene
Bunod Ophthalmic Solution 0.024%: Analysis of Patient Longitudinal
Data." W224 ABC, Orange County
Convention Center, Friday, Oct. 25,
2019 at 2:00 p.m. ET.
- Rah M et al. "Identifying Opportunities for Contact Lens Wear
Through Challenges Experienced by Presbyopic Astigmatic Patients
Wearing Spectacles." Poster #50, Exhibit Hall WD1, Orange County Convention Center, Friday, Oct. 25, 2019 from 9 a.m. to 3 p.m. ET.
- Reindel WT et al. "Progressive Multifocal Contact Lenses for
the Astigmatic Presbyope: A Comparison of Power Profiles Across
Near, Intermediate and Distance Zones." Poster #51, Exhibit Hall
WD1, Orange County Convention
Center, Friday, Oct. 25, 2019 from
9 a.m. to 3 p.m. ET.
- Sanfilippo C et al. "Antibiotic Resistance Rates Among
Bacterial Pathogens Collected from the Cornea in ARMOR." Poster
#54, Exhibit Hall WD1, Orange
County Convention Center, Thursday,
Oct. 24, 2019 from 4:30 to 6:30 p.m.
ET.
- Sanfilippo C et al. "Antibiotic Resistance Trends Among Ocular
Pathogens in the United States:
Ten-Year Results from the ARMOR Study." Poster #55, Exhibit Hall
WD1, Orange County Convention
Center, Thursday, Oct. 24, 2019 from
4:30 to 6:30 p.m. ET.
Important Safety Information for BESIVANCE®
(besifloxacin ophthalmic suspension) 0.6%
Indication
BESIVANCE® (besifloxacin ophthalmic
suspension) 0.6% is a quinolone antimicrobial indicated for the
treatment of bacterial conjunctivitis caused by susceptible
isolates of the following bacteria: Aerococcus viridans*,
CDC coryneform group G, Corynebacterium pseudodiphtheriticum*,
Corynebacterium striatum*, Haemophilus influenzae, Moraxella
catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*,
Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus
hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*,
Streptococcus mitis group, Streptococcus oralis,
Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10
infections.
Important Safety Information
- BESIVANCE® is not for injection into the eye.
- As with other anti-infectives, prolonged use of BESIVANCE® may
result in overgrowth of non-susceptible organisms, including fungi.
If super-infection occurs, discontinue use and institute
alternative therapy.
- Patients should not wear contact lenses if they have signs or
symptoms of bacterial conjunctivitis or during the course of
therapy with BESIVANCE®.
- The most common adverse event reported in approximately 2% of
patients treated with BESIVANCE® was conjunctival redness. Other
adverse events reported in patients receiving BESIVANCE® occurring
in approximately 1-2% of patients included: blurred vision, eye
pain, eye irritation, eye pruritus and headache.
- Safety and effectiveness in infants below one year of age have
not been established.
Click here for full Prescribing Information for
BESIVANCE®.
Important Safety Information for VYZULTA®
(latanoprostene bunod ophthalmic solution), 0.024%
INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution),
0.024% is indicated for the reduction of intraocular pressure (IOP)
in patients with open-angle glaucoma or ocular
hypertension.
IMPORTANT SAFETY INFORMATION
- Increased pigmentation of the iris and periorbital tissue
(eyelid) can occur. Iris pigmentation is likely to be
permanent
- Gradual changes to eyelashes, including increased length,
increased thickness, and number of eyelashes, may occur. These
changes are usually reversible upon treatment discontinuation
- Use with caution in patients with a history of intraocular
inflammation (iritis/uveitis). VYZULTA should generally not be used
in patients with active intraocular inflammation
- Macular edema, including cystoid macular edema, has been
reported during treatment with prostaglandin analogs. Use with
caution in aphakic patients, in pseudophakic patients with a torn
posterior lens capsule, or in patients with known risk factors for
macular edema
- There have been reports of bacterial keratitis associated with
the use of multiple-dose containers of topical ophthalmic products
that were inadvertently contaminated by patients
- Contact lenses should be removed prior to the administration of
VYZULTA and may be reinserted 15 minutes after administration
- Most common ocular adverse reactions with incidence ≥2% are
conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%),
and instillation site pain (2%)
Please see full prescribing information at
www.bausch.com/vyzulta.
Important Safety Information for LOTEMAX® SM (loteprednol
etabonate ophthalmic gel) 0.38%
INDICATION
LOTEMAX® SM (loteprednol etabonate
ophthalmic gel) 0.38% is a corticosteroid indicated for the
treatment of post-operative inflammation and pain following ocular
surgery.
IMPORTANT SAFETY INFORMATION
- LOTEMAX® SM, as with other ophthalmic corticosteroids, is
contraindicated in most viral diseases of the cornea and
conjunctiva including epithelial herpes simplex keratitis
(dendritic keratitis), vaccinia, and varicella, and also in
mycobacterial infection of the eye and fungal diseases of ocular
structures.
- Prolonged use of corticosteroids may result in glaucoma with
damage to the optic nerve, defects in visual acuity and fields of
vision. Steroids should be used with caution in the presence of
glaucoma. If LOTEMAX® SM is used for 10 days or longer, IOP should
be monitored.
- Use of corticosteroids may result in posterior subcapsular
cataract formation.
- The use of steroids after cataract surgery may delay healing
and increase the incidence of bleb formation. In those with
diseases causing thinning of the cornea or sclera, perforations
have been known to occur with the use of topical steroids. The
initial prescription and renewal of the medication order should be
made by a physician only after examination of the patient with the
aid of magnification such as slit lamp biomicroscopy and, where
appropriate, fluorescein staining.
- Prolonged use of corticosteroids may suppress the host response
and thus increase the hazard of secondary ocular infections. In
acute purulent conditions, steroids may mask infection or enhance
existing infections.
- Employment of a corticosteroid medication in the treatment of
patients with a history of herpes simplex requires great caution.
Use of ocular steroids may prolong the course and may exacerbate
the severity of many viral infections of the eye (including herpes
simplex).
- Fungal infections of the cornea are particularly prone to
develop coincidentally with long-term local steroid application.
Fungus invasion must be considered in any persistent corneal
ulceration where a steroid has been used or is in use. Fungal
cultures should be taken when appropriate.
- Contact lenses should not be worn when the eyes are
inflamed.
- There were no treatment-emergent adverse drug reactions that
occurred in more than 1% of subjects in the three times daily group
compared to vehicle.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
Click here for full Prescribing Information for
LOTEMAX® SM.
About Bausch + Lomb
Bausch + Lomb, a wholly owned
subsidiary of Bausch Health Companies Inc., is a leading global eye
health organization that is solely focused on helping people see
better. Its core businesses include over-the-counter products,
dietary supplements, eyecare products, ophthalmic pharmaceuticals,
contact lenses, lens care products, ophthalmic surgical devices and
instruments. Bausch + Lomb develops, manufactures and markets one
of the most comprehensive product portfolios in the industry, which
is available in more than 100 countries. For more information,
visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in Bausch Health's
most recent annual or quarterly report and detailed from time to
time in Bausch Health's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Bausch Health undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
®/TM are trademarks of Bausch & Lomb Incorporated
or its affiliates.
Any other product/brand names are trademarks of the respective
owners.
© 2019 Bausch & Lomb Incorporated or its affiliates.
MTB.0448.USA.19
Bausch Health
Investor:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com mailto:
|
(514)
856-855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-announces-new-scientific-and-clinical-analyses-to-be-presented-during-the-american-academy-of-ophthalmology-and-american-academy-of-optometry-annual-meetings-300932783.html
SOURCE Bausch Health Companies Inc.